Evotec and Crohn’s & Colitis Foundation Join Forces to Advance IBD Treatments

To enhance drug development and provide novel treatments for Inflammatory Bowel Disease, which encompasses ulcerative colitis and Crohn’s disease, Evotec and the Crohn’s & Colitis Foundation have unveiled their partnership. 

Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract, encompassing disorders such as Crohn’s disease and ulcerative colitis. 

The collaboration will utilize Evotec’s comprehensive study findings to propel the progress of medications for fibrosis and compromised intestinal barrier function, addressing two major concerns for individuals with IBD. 

Dr Matthias Evers, the leading business executive, commented, “Mission-driven foundations like the Crohn’s & Colitis Foundation are an essential part of the healthcare ecosystem as they drive medical progress in areas of significant unmet need that would otherwise not be pursued.” 

Dr Evers went on to add, “We are fully aligned on our mission to create access to novel therapeutics and look forward to leveraging both Evotec’s translational experience as well as our fully integrated drug discovery powerhouse within the foundation’s IBD therapeutics incubator.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.